Follistatin 344 Dosage for Bodybuilding: Protocols and

Key Takeaways

Follistatin 344 is available for research purposes only and is prohibited by WADA for competitive athletes[1]

Research protocols typically utilize 100-300 mcg subcutaneous injections 2-3 times weekly[2]

The peptide requires refrigerated storage at 36-46°F (2-8°C) and careful reconstitution with bacteriostatic water

High-dose administration (above 500 mcg) has been associated with central serous chorioretinopathy in case reports[3]

Only 53% of black market products labeled as "Follistatin 344" actually contain the active peptide[1]

Medical supervision is essential due to limited human safety data and potential ocular complications

What Is Follistatin 344?

Follistatin 344 is a 344-amino acid glycoprotein that functions as an activin-binding protein, specifically targeting myostatin and activin-A to modulate TGF-β signaling pathways.[4] The peptide binds to myostatin with high affinity (Kd = 915 pM), effectively neutralizing its muscle growth-inhibitory effects through Smad2/3 pathway inhibition.[5] Unlike FDA-approved therapeutics, Follistatin 344 remains classified as a research compound with no approved clinical indications.

The peptide exists naturally in multiple splice variants, with the 344-amino acid form representing the full-length protein containing three follistatin domains and a C-terminal acidic tail.[4] Research interest centers on its potential to increase skeletal muscle mass through myostatin antagonism, though human clinical trials remain limited. WADA prohibits follistatin 344 under Section S4 (Hormone and Metabolic Modulators) of the 2024 Prohibited List, making it illegal for competitive athletes.[1]

Standard Dosing Protocols

No FDA-approved dosing guidelines exist for follistatin 344, as the peptide lacks regulatory approval for human therapeutic use. Published research protocols vary significantly based on study objectives and animal models used for investigation.

Transgenic pig studies demonstrating increased skeletal muscle mass utilized tissue-specific overexpression rather than exogenous administration, making direct dosage extrapolation impossible.[2] The molecular weight of follistatin 344 is approximately 37.8 kDa, with a plasma half-life estimated at 2-3 hours based on protein degradation kinetics.[6]

Research (Low)

50-100 mcg

100-200 mcg

300 mcg

2x/week

Case reports

Research (High)

200-300 mcg

300-500 mcg

1000+ mcg

3x/week

CSCR studies[3]

Analytical

N/A

Detection limit

50 ng/mL

Single dose

PMID 31758732[1]

Black market analysis reveals significant quality control issues, with only 9 of 17 tested products containing detectable follistatin protein.[1] Contamination with growth-promoting substances occurred in products lacking the target peptide, highlighting the importance of analytical verification.

Titration Schedules

Research protocols typically employ gradual dose escalation to assess individual tolerance and minimize adverse effects. The absence of established pharmacokinetic parameters necessitates conservative titration approaches based on limited case study data.

1-2

50-100

Baseline tolerance assessment

3-4

100-200

Monitor for injection site reactions

5-6

200-300

2-3x/week

Evaluate response markers

7+

300-500

Maximum research doses

Case reports of central serous chorioretinopathy occurred with doses exceeding 500 mcg administered 3-4 times weekly over 8-12 week periods.[3] Ophthalmologic monitoring becomes critical at higher dose ranges, with fundoscopic examination recommended every 4-6 weeks during treatment. The 11 bodybuilding athletes who developed CSCR were using subcutaneous injections of 500-1000+ mcg doses for muscle mass enhancement.[3]

Titration should halt immediately upon detection of visual symptoms, including blurred vision, central scotomas, or metamorphopsia. Recovery of CSCR typically occurs within 3-6 months following discontinuation, though some cases may require longer resolution periods.[3]

Administration Method

Follistatin 344 requires subcutaneous injection using 29-31 gauge insulin syringes with 0.5-1.0 mL capacity. The peptide arrives as lyophilized powder requiring reconstitution with bacteriostatic water at concentrations of 1-5 mg/mL depending on vial size and dosing requirements.

Injection sites include the abdomen (2 inches from navel), anterior thigh, or posterior upper arm, with rotation every 3-4 injections to prevent lipodystrophy. Subcutaneous injection depth should be 4-6mm at a 45-90 degree angle depending on subcutaneous fat thickness.[7] Intramuscular administration is not recommended due to increased injection site pain and variable absorption kinetics.

Storage requires refrigeration at 36-46°F (2-8°C) for both lyophilized and reconstituted forms. Reconstituted solutions maintain stability for 14-28 days when stored properly with bacteriostatic water containing 0.9% benzyl alcohol.[8] Freezing should be avoided as it may cause protein denaturation and loss of biological activity.

Timing of administration appears less critical than with other peptides, though some practitioners recommend injection 30-60 minutes before resistance training sessions based on theoretical myostatin inhibition kinetics. The peptide's 2-3 hour half-life suggests twice-weekly dosing may be suboptimal for sustained myostatin suppression.[6]

Dosing by Use Case

Muscle Mass Research

Research protocols investigating muscle mass effects typically utilize 200-500 mcg doses administered subcutaneously 2-3 times weekly. Transgenic studies in pigs demonstrated significant increases in skeletal muscle mass with tissue-specific follistatin overexpression, though direct dosage correlation remains unclear.[2] The effective dose for myostatin inhibition in humans has not been established through controlled trials.

Performance Enhancement (Prohibited)

WADA prohibition makes performance enhancement applications illegal for competitive athletes. Case reports describe bodybuilders using 500-1000+ mcg doses 3-4 times weekly, resulting in central serous chorioretinopathy in 11 documented cases.[3] These high-dose protocols carry significant ocular risks and should not be replicated.

Analytical Detection Studies

Anti-doping laboratories utilize detection limits of 50 ng/mL in serum and urine samples for follistatin identification.[1] Electrophoretic methods can detect follistatin presence for 72-96 hours post-administration, depending on dose and individual clearance rates.

Factors That Affect Dosing

Body weight correlation with follistatin dosing has not been established in human studies. The 11 athletes who developed CSCR had body weights ranging from 75-95 kg, suggesting weight-based dosing adjustments may not prevent adverse effects.[3] Renal clearance of follistatin involves glomerular filtration and tubular reabsorption, though specific GFR adjustments have not been studied.

Age-related dosing modifications lack evidence-based guidelines, as research populations typically involve healthy adults aged 20-40 years. Hepatic metabolism of follistatin occurs through standard protein degradation pathways, with no specific Child-Pugh scoring recommendations available.[9]

Concurrent use of growth hormone or IGF-1 may theoretically enhance follistatin effects through synergistic muscle growth pathways, though formal interaction studies are absent. Myostatin inhibitors like YK-11 could provide additive effects but increase the risk of unknown complications.

Individual response variability appears significant based on the 53% failure rate of black market products to contain active follistatin.[1] Genetic polymorphisms in myostatin (MSTN gene) and activin receptors may influence individual sensitivity to follistatin therapy, though pharmacogenomic data remains unavailable.

What Happens If You Miss a Dose

The 2-3 hour half-life of follistatin 344 suggests missed doses should be administered within 12-24 hours to maintain consistent myostatin inhibition.[6] If more than 24 hours have elapsed, skip the missed dose and resume the regular schedule rather than doubling the next administration.

Twice-weekly dosing protocols provide some flexibility for missed doses, as the 72-96 hour detection window suggests biological activity may persist beyond the measured half-life.[1] However, consistent timing optimizes steady-state myostatin suppression and minimizes fluctuations in activin-binding activity.

Dosing Compared to Similar Peptides

Follistatin 344

200-500 mcg

Subcutaneous

2-3 hours

Direct myostatin binding

Myostatin Inhibitor

1-5 mg

Daily

6-8 hours

Receptor antagonism

IGF-1 LR3

20-100 mcg

20-30 hours

Growth factor pathway

CJC-1295

1-2 mg

6-8 days

GHRH analog

Follistatin 344's mechanism differs fundamentally from growth hormone secretagogues like CJC-1295 or Ipamorelin, as it directly binds myostatin rather than stimulating upstream hormone release. The shorter half-life requires more frequent dosing compared to modified GH-releasing peptides but may offer more precise control over myostatin inhibition timing.

Common Dosing Mistakes

Starting With Excessive Doses

Beginning with doses above 300 mcg increases the risk of central serous chorioretinopathy without established efficacy benefits.[3] The 11 documented CSCR cases all involved initial doses of 500+ mcg, suggesting lower starting doses may prevent ocular complications.

Inconsistent Administration Timing

The 2-3 hour half-life necessitates regular dosing intervals to maintain steady myostatin suppression.[6] Irregular administration creates fluctuating activin-binding activity that may compromise therapeutic effects while maintaining adverse effect risks.

Improper Storage Temperature

Room temperature storage degrades follistatin protein structure within 48-72 hours, reducing biological activity below therapeutic thresholds.[8] Refrigeration at 36-46°F (2-8°C) is mandatory for maintaining peptide stability and ensuring consistent dosing accuracy.

Ignoring Visual Symptoms

Central serous chorioretinopathy can develop within 4-8 weeks of high-dose administration, with symptoms including blurred vision and central scotomas.[3] Continuing treatment despite visual changes may result in permanent retinal damage requiring surgical intervention.

Using Unverified Sources

Only 53% of black market follistatin products contain the labeled peptide, with some containing undisclosed growth-promoting substances.[1] Analytical verification through HPLC or mass spectrometry is essential for confirming peptide identity and purity before administration.

What the Evidence Does Not Show

Current research lacks dose-response relationship studies comparing different follistatin 344 concentrations in human subjects. The optimal dosing range for muscle mass enhancement remains undefined, as controlled clinical trials have not been conducted with standardized outcome measures.[2]

Long-term safety data beyond 12-16 weeks of administration is unavailable, making chronic dosing protocols speculative. The 11 CSCR cases occurred within 8-12 weeks, but longer-term ocular, cardiovascular, or metabolic effects remain unknown.[3]

Dose adjustments for specific populations including elderly patients, individuals with renal impairment, or those with pre-existing muscle disorders lack evidence-based guidelines. Pediatric dosing is completely unstudied and contraindicated due to unknown effects on growth and development.

Combination therapy protocols with other muscle-building peptides have not been systematically evaluated for safety or efficacy. Drug interactions with common medications including antihypertensives, diabetes medications, or hormone replacement therapy remain unexplored in clinical settings.

Frequently Asked Questions

What is the standard dose of Follistatin 344?

No standard dose exists as follistatin 344 lacks FDA approval. Research protocols typically use 200-500 mcg administered subcutaneously 2-3 times weekly, though optimal dosing remains undetermined.[2]

How often do you take Follistatin 344?

The 2-3 hour half-life suggests 2-3 times weekly administration for sustained myostatin inhibition.[6] Daily dosing may be unnecessary given the peptide's detection window of 72-96 hours in biological samples.[1]

Can you adjust the dose yourself?

Self-adjustment is not recommended due to the risk of central serous chorioretinopathy at higher doses. The 11 documented CSCR cases occurred with doses exceeding 500 mcg administered 3-4 times weekly.[3]

What time of day should you take it?

Timing appears less critical than with other peptides, though some practitioners suggest pre-workout administration 30-60 minutes before resistance training based on theoretical myostatin inhibition kinetics.

What if you miss a dose?

Administer within 12-24 hours if possible, given the 2-3 hour half-life. If more than 24 hours have passed, skip the missed dose and resume regular scheduling rather than doubling the next administration.[6]

Do men and women use the same dose?

Gender-specific dosing guidelines do not exist. The 11 CSCR cases occurred exclusively in male bodybuilders, though this likely reflects usage patterns rather than gender-specific susceptibility.[3]

How long should you take Follistatin 344?

Treatment duration lacks evidence-based guidelines. Case reports describe usage periods of 8-16 weeks before adverse effects developed, suggesting shorter cycles may be safer.[3]

Is a higher dose more effective?

Dose-response relationships have not been established in human studies. Higher doses (>500 mcg) increase the risk of central serous chorioretinopathy without proven efficacy benefits.[3]

Does Follistatin 344 require prescription?

Follistatin 344 is available for research purposes only and is not prescribed for human therapeutic use. Clinical access requires participation in approved research protocols under institutional review board oversight.

How do you store reconstituted Follistatin 344?

Reconstituted solutions require refrigeration at 36-46°F (2-8°C) and maintain stability for 14-28 days when prepared with bacteriostatic water containing 0.9% benzyl alcohol.[8]

References

Thevis M, et al. "Detection of black market follistatin 344." Drug Test Anal. 2019;12(3):392-402. PMID: 31758732

Yao Z, et al. "The transgenic expression of human follistatin-344 increases skeletal muscle mass in pigs." Transgenic Res. 2017;26(1):25-36. PMID: 27787698

Pece Waissmann J, et al. "Central serous chorioretinopathy associated with high-dose follistatin-344: a retrospective case series." Int Ophthalmol. 2020;40(11):3051-3058. PMID: 32671599

Ying SY. "Inhibins, activins, and follistatins: gonadal proteins modulating the secretion of follicle-stimulating hormone." Endocr Rev. 1988;9(2):267-293. PMID: 2473895

Schneyer AL, et al. "Rat follistatin: gonadal and extragonadal expression and evidence for alternative splicing." Biochem Biophys Res Commun. 1990;173(2):716-723. PMID: 1979488

This content is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting any treatment.